Cromatina / Epigenética
Los inhibidores de cromatina/epigenética son compuestos que modulan la estructura y función de la cromatina o interfieren con modificaciones epigenéticas, como la metilación del ADN y la modificación de histonas. Estos inhibidores son herramientas esenciales para estudiar la regulación de la expresión génica y el papel de la epigenética en enfermedades como el cáncer, los trastornos neurológicos y las anomalías del desarrollo. Al dirigirse a los procesos epigenéticos, estos inhibidores pueden alterar los patrones de expresión génica y ofrecer nuevas vías terapéuticas. En CymitQuimica, ofrecemos una amplia selección de inhibidores de cromatina/epigenética de alta calidad para apoyar su investigación en biología molecular, genética y epigenética.
Subcategorías de "Cromatina / Epigenética"
Se han encontrado 2235 productos de "Cromatina / Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PF-03622905
CAS:<p>PF-03622905: potent ATP-competitive PKC inhibitor, IC50: 5.6-74.1 nM for PKCα/βI/βII/γ/θ, high specificity for PKC.</p>Fórmula:C24H35N7O3Forma y color:SolidPeso molecular:469.59Ep300/CREBBP-IN-8
CAS:<p>Ep300/CREBBP-IN-8, IC50: 0.014/0.018 μM, potent Ep300/CREBBP inhibitor, oral, for cancer research.</p>Fórmula:C25H27F2N5O3Forma y color:SolidPeso molecular:483.51BRCA1-IN-1
CAS:<p>BRCA1-IN-1 is a novel small-molecule-like inhibitor of BRCA1 (IC50: 0.53 μM; Ki: 0.71 μM).</p>Fórmula:C27H33F2N4O6PPureza:98%Forma y color:SolidPeso molecular:578.54HDAC-IN-68 hydrochloride
<p>HDAC-IN-68 (hydrochloride) (Compound 29) is an HDACs inhibitor with an IC50 value of 0.04 μM and induces microtubule fragmentation by activating katanin, a microtubule-severing protein. It is applicable in cancer research.</p>Fórmula:C27H25ClN8O6Peso molecular:592.15856Biguanide
CAS:<p>Biguanide can reduce oxidative stress in rats with hyperglycemia.</p>Fórmula:C2H7N5Forma y color:SolidPeso molecular:101.11BRD3067
CAS:<p>BRD3067, a Tubacin derivative, inhibits HDAC6 (IC50 15 nM) and acts as a negative control for Tubacin A, showing anticancer and anti-inflammatory effects.</p>Fórmula:C21H23N3O2Pureza:98%Forma y color:SolidPeso molecular:349.43Bryostatin 3
CAS:<p>Bryostatin 3 is a protein kinase C activator.</p>Fórmula:C46H64O17Pureza:98%Forma y color:SolidPeso molecular:888.99MSC2504877
CAS:<p>MSC2504877 inhibits tankyrase, boosts CDK4/6 inhibitors, blocks Cyclin D2/E2 upregulation, and strengthens phospho-Rb suppression.</p>Fórmula:C17H18N2O2Pureza:99.72%Forma y color:SoildPeso molecular:282.34pan-BET/BD2-IN-1
<p>Pan-BET/BD2-IN-1 (compound 6b) is a selective BET protein inhibitor with BRDT-1Ki of 1.05 μM and BRD4-1Ki of 0.68 μM. It effectively inhibits the growth of MM.1S cancer cells with an IC50 value of 2.6 μM.</p>Forma y color:Odour SolidPOI ligand 1
<p>POI ligand 1 serves as a template for the non-selective HDAC inhibitor Vorinostat. It functions as a target protein ligand (PROTAC target protein ligand) in the creation of PROTAC HDAC degraders with anti-tumor properties. Additionally, POI ligand 1 is utilized in the synthesis of FF2049.</p>Fórmula:C14H21N3O3Forma y color:SolidPeso molecular:279.335SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Fórmula:C42H43N13O7SForma y color:SolidPeso molecular:873.94BRD4 degrader AT1
CAS:<p>BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a Kd of 44 nM for Brd4BD2 in cells.</p>Fórmula:C48H58ClN9O5S3Pureza:98%Forma y color:SolidPeso molecular:972.68Malantide
CAS:<p>Malantide, a synthetic dodecapeptide, boosts and measures PKA activity by undergoing PKA-induced phosphorylation.</p>Fórmula:C72H124N22O21Pureza:98%Forma y color:SolidPeso molecular:1633.89dBET23
CAS:<p>dBET23 is a BRD4 degrader.</p>Fórmula:C43H45ClN8O9SForma y color:SolidPeso molecular:885.38CD532 hydrochloride
<p>CD532 hydrochloride, potent Aurora A inhibitor (IC50=45 nM), hampers MYCN protein, changes AURKA's shape, aids cancer research.</p>Forma y color:SolidmTOR/HDAC-IN-1
CAS:<p>mTOR/HDAC-IN-1, a dual inhibitor for mTOR & HDAC1 with IC50s 0.49 & 0.91 nM, potential anti-cancer agent.</p>Fórmula:C23H23N11O3Forma y color:SolidPeso molecular:501.5MT1
CAS:<p>MT1, a bivalent chemical probe targeting BET bromodomains, demonstrates an IC50 value of 0.789 nM for BRD4(1).</p>Fórmula:C54H66Cl2N10O9S2Forma y color:SolidPeso molecular:1134.2XF056-132
CAS:<p>XF056-132 is a potent WDR5 (WD40 repeat domain protein 5) PROTAC degrader [1] .</p>Fórmula:C51H57F4N9O7SForma y color:SolidPeso molecular:1016.11HDAC-IN-26
CAS:<p>HDAC-IN-26 is a highly selective class I HDAC inhibitor with an EC 50 value of 4.7 nM.</p>Fórmula:C24H28FN5O3Forma y color:SolidPeso molecular:453.518CBP/p300-IN-14
CAS:<p>CBP/p300-IN-14, patent WO2021213521A1's compound 27, inhibits CBP/EP300 with 3.3 nM IC50.</p>Fórmula:C30H31F2N7O2Forma y color:SolidPeso molecular:559.622MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Fórmula:C23H26N4O2SForma y color:SolidPeso molecular:422.54DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Fórmula:C25H38N4O3Forma y color:SolidPeso molecular:442.59Ep300/CREBBP-IN-2
CAS:<p>Ep300/CREBBP-IN-2: Potent, oral Ep300 & CREBBP inhibitor; IC50s: 0.052μM & 0.148μM; cancer research.</p>Fórmula:C26H27F3N4O4Forma y color:SolidPeso molecular:516.51mUNO
CAS:<p>mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to murine CD206, targeting tumor-associated macrophages that express CD206/MRC1. Additionally, mUNO can interact with human recombinant CD206.</p>Fórmula:C22H39N7O8SForma y color:SolidPeso molecular:561.652EZH2-IN-15
CAS:<p>A compound inhibits EZH2, overexpressed in cancers, affecting Treg activity and innate immunity.</p>Fórmula:C32H44N4O4Pureza:99.88%Forma y color:SolidPeso molecular:548.72ATF3 inducer 1
CAS:<p>ATF3 inducer 1 is an ATF3 inducer with lipid-lowering activity, alleviating glucose intolerance and insulin resistance induced by high-fat diet (HFD).</p>Fórmula:C12H10N2O3Pureza:99.04%Forma y color:SoildPeso molecular:230.22HD-TAC7
<p>HD-TAC7 is a PROTAC HDAC degrader; IC50s: HDAC1 (3.6μM), HDAC2 (4.2μM), HDAC3 (1.1μM); reduces NF-κB p65; researched for asthma, COPD.</p>Fórmula:C33H32FN7O7Forma y color:SolidPeso molecular:657.65OARV-771
CAS:<p>OARV-771: VHL-based PROTAC targeting BET; DC50: Brd4-6nM, Brd2-1nM, Brd3-4nM; enhanced cell permeability.</p>Fórmula:C49H59ClN8O8S2Forma y color:SolidPeso molecular:987.62(S,R,S)-AHPC-C5-COOH
CAS:<p>E3 ligase ligand-linker '(S,R,S)-AHPC-C5-COOH' for PROTACs, VH032 inhibits VHL/HIF-1α with 185 nM Kd, may aid anemia and ischemic disease research.</p>Fórmula:C29H42N4O5SPureza:98%Forma y color:SolidPeso molecular:558.73PROTAC SMARCA2/4-degrader-27
CAS:<p>PROTAC SMARCA2/4-degrader-27 (PROTAC 2) serves as a targeted degrader, utilizing PROTAC technology to degrade both SMARCA2 and SMARCA4.</p>Fórmula:C49H58FN9O6SForma y color:SolidPeso molecular:920.11Cath-L-dBET1
<p>Cath-L-dBET1 is a PROTAC degrader targeting BRD4. It has an IC50 value of 2.8 μM in MDA-MB-231 cells. Activated by cathepsin L (Cath-L), Cath-L-dBET1 recruits E3 ubiquitin ligase to degrade BRD4 via the ubiquitin-proteasome system. Hyp-dBET1 is applicable for antitumor research.</p>Forma y color:Odour SolidJHDM-IN-1
CAS:<p>JHDM-IN-1 inhibits JHDMs; IC50: 3.4 μM JMJD2C, 4.3 μM JMJD2A, 5.9 μM JMJD2E, 10 μM PHF8, 43 μM JMJD3.</p>Fórmula:C27H29N3O6Forma y color:SolidPeso molecular:491.54ZINC000014708529
<p>ZINC000014708529 is a potent SIRT7 inhibitor exhibiting high affinity for SIRT7 and is utilized in cancer research [1].</p>Forma y color:Odour SolidSIRT1/2/3-IN-1
CAS:<p>Potent SIRT1/2/3-IN-1 inhibits SIRT1/2/3 with IC50: 0.54, 0.25, 0.72 μM; used in cancer research.</p>Fórmula:C46H63N9O8S2Forma y color:SolidPeso molecular:934.18NF-κB/HIF-1α-IN-1
<p>NF-κB/HIF-1α-IN-1 (compound 9c) effectively inhibits the NF-κB activation pathway and demonstrates selective antifibrotic activity. This compound exhibits no significant cytotoxicity in NCI tumor cell lines. In rat models, NF-κB/HIF-1α-IN-1 successfully ameliorates liver fibrosis, suppresses the expression levels of NF-κB and HIF-1α, and induces Nrf2.</p>Fórmula:C24H27N7O4Forma y color:SolidPeso molecular:477.21245MZP-55
CAS:<p>MZP-55 is a selective BRD3/4 degrader based on PROTAC technology(Brd4BD2 with Kd of 8 nM)</p>Fórmula:C57H70ClN7O10SPureza:98%Forma y color:SolidPeso molecular:1080.73TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Fórmula:C23H21FN4O2Forma y color:SolidPeso molecular:404.16485N-Desmethyltamoxifen
CAS:<p>N-Desmethyltamoxifen, tamoxifen's main human metabolite, regulates AML cell ceramide metabolism and is a more potent PKC inhibitor than tamoxifen.</p>Fórmula:C25H27NOPureza:98%Forma y color:SolidPeso molecular:357.49AURKA against 1
<p>Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.</p>Fórmula:C28H32FN9O2Forma y color:SolidPeso molecular:545.61MS2133
<p>MS2133 is a DOT1L PROTAC degrader. It facilitates the ubiquitination and degradation of DOT1L in THP-1 and MV4-11 cells, with DC50 values of 56 nM and 25 nM, respectively, and reduces H3K79 methylation. MS2133 also inhibits the growth of MLL-r leukemia cells, demonstrating anticancer activity.</p>Fórmula:C58H66ClF3N14O11S2Forma y color:SolidPeso molecular:1290.41175OKI-006
CAS:<p>OKI-006 is an oral HDAC inhibitor with potential for cancer research, derived from largazole.</p>Fórmula:C21H30N4O5S2Forma y color:SolidPeso molecular:482.62PROTAC SMARCA2/4-degrader-31
CAS:<p>PROTAC SMARCA2/4-degrader-31 (Compound I-280) serves as a degrader for the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF complex. It effectively degrades SMARCA2 in A549 cells and SMARCA4 in MV411 cells, both with a degradation concentration (DC50) of less than 100 nM.</p>Fórmula:C44H51N11O4Forma y color:SolidPeso molecular:797.95PROTAC BRD4-binding moiety 1
CAS:<p>BRD4-binding moiety 1 links to cereblon, forming a PROTAC that degrades BRD4 efficiently.</p>Fórmula:C23H21N3O2Pureza:98%Forma y color:SolidPeso molecular:371.43(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine
CAS:<p>(S,R,S)-AHPC-C2-amide targets Smad3 degradation and boosts HIF-α; it has anti-fibrotic and renal protective roles.</p>Fórmula:C41H46N6O6SForma y color:SolidPeso molecular:750.91SGC3027
<p>SGC3027 is an inhibitor of histone methyltransferase,also is a first potent, selective and cell active chemical probe for PRMT7.</p>Fórmula:C41H47ClN6O6SPureza:98%Forma y color:SolidPeso molecular:787.37(rel)-Tranylcypromine D5 hydrochloride
CAS:<p>(rel)-Tranylcypromine D5 hydrochloride is a deuterium labeled (rel)-Tranylcypromine hydrochloride.</p>Fórmula:C9H12ClNPureza:98%Forma y color:SolidPeso molecular:174.682TAS-119
CAS:<p>TAS-119 (TAS-2104) is an orally available, selective and potent inhibitor of Aurora A with an IC50 of 1.0 nM.TAS-119 also inhibits Aurora B with an IC50 of 95</p>Fórmula:C23H22Cl2FN5O3Pureza:99.65%Forma y color:SolidPeso molecular:506.36KDM4 ligand-1
<p>KDM4ligand-1 is a ligand targeting the protein (histone lysine demethylase KDM4) in PROTACs. It can be utilized for the synthesis of PROTACs.</p>Forma y color:Odour SolidEchinomycin
CAS:<p>Echinomycin (Quinomycin A) is a quinoxaline antibiotic and a DNA-intercalating peptide that inhibits hypoxia-inducible factor-1 (HIF-1) DNA binding activity.</p>Fórmula:C51H64N12O12S2Pureza:95%Forma y color:SolidPeso molecular:1101.26
